(Q44650366)

5 December 2017

title

Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer (English)

1 reference

5 December 2017

0 references

1 reference

Nils D Arvold

1

1 reference

5 December 2017

David P Ryan

2

1 reference

5 December 2017

Andrzej Niemierko

3

1 reference

5 December 2017

Lawrence S Blaszkowsky

4

1 reference

5 December 2017

Eunice L Kwak

5

1 reference

5 December 2017

Jennifer Y Wo

6

1 reference

5 December 2017

Jill N Allen

7

1 reference

5 December 2017

Jeffrey W Clark

8

1 reference

5 December 2017

Raymond C Wadlow

9

1 reference

5 December 2017

Andrew X Zhu

10

1 reference

5 December 2017

Carlos Fernandez-Del Castillo

11

1 reference

5 December 2017

Theodore S Hong

12

1 reference

5 December 2017

language of work or name

English

0 references

publication date

21 October 2011

1 reference

5 December 2017

1 reference

5 December 2017

volume

118

1 reference

5 December 2017

issue

12

1 reference

5 December 2017

page(s)

3026-3035

1 reference

Laparoscopy and peritoneal cytology in the staging of pancreatic cancer

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26633

Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26633

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26633

Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26633

Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26633

Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26633

Pancreatic cancer tumor size on CT scan versus pathologic specimen: implications for radiation treatment planning

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26633

A systematic review of resectability and survival after concurrent chemoradiation in primarily unresectable pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26633

Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26633

Borderline resectable pancreatic cancer: the importance of this emerging stage of disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26633

Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26633

Neoadjuvant therapy may lead to successful surgical resection and improved survival in patients with borderline resectable pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26633

Outcomes and tolerability of chemoradiation therapy for pancreatic cancer patients aged 75 years or older

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26633

Using economic analysis to evaluate the potential of multimodality therapy for elderly patients with locally advanced pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26633

Locally advanced pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26633

Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26633

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26633

Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26633

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26633

Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26633

Gemcitabine, paclitaxel, and radiation for locally advanced pancreatic cancer: a Phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26633

Phase I trial of strictly time-scheduled gemcitabine and cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26633

Docetaxel and Radiotherapy and Pancreatic Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26633

Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26633

A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26633

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26633

Impact of Chemoradiotherapy After Disease Control With Chemotherapy in Locally Advanced Pancreatic Adenocarcinoma in GERCOR Phase II and III Studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26633

Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26633

inferred from DOI database lookup

7 January 2021

based on heuristic

Long-term results of intraoperative electron beam irradiation (IOERT) for patients with unresectable pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26633

inferred from DOI database lookup

7 January 2021

based on heuristic

Induction Gemcitabine and Stereotactic Body Radiotherapy for Locally Advanced Nonmetastatic Pancreas Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26633

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CNCR.26633

1 reference

5 December 2017

1 reference